Immune SupportStudiedCompoundable

VIP

Vasoactive Intestinal Peptide · VPAC1 and VPAC2 receptor agonism; cAMP elevation via adenylyl cyclase; promotes Th2 tolerance over Th1/Th17 inflammatory responses; inhibits TNF-α, IL-12, and iNOS production; causes smooth muscle relaxation and bronchodilation

Not medical advice. For educational and research reference only.

Typical Dose

50 mcg intranasally twice daily (CIRS protocol) or 200–400 ng/kg IV infusion

Route

Intranasal / Injectable

Cycle

Protocol-dependent (CIRS: months of therapy)

Storage

2–8°C Refrigerated

What is VIP?

Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.

Mechanism of Action

VPAC1 and VPAC2 receptor agonism; cAMP elevation via adenylyl cyclase; promotes Th2 tolerance over Th1/Th17 inflammatory responses; inhibits TNF-α, IL-12, and iNOS production; causes smooth muscle relaxation and bronchodilation

Target: VPAC1 receptor, VPAC2 receptor

Research Indications

Immune ModulationEffective

Research shows modulation of immune cell activity and inflammatory response

Inflammation ControlEffective

May reduce systemic and localized inflammatory markers

Infection ResistanceModerate

Some evidence for improved pathogen defense mechanisms

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting Dose250 mcg3x weeklySubcutaneous injection
Maintenance Dose500 mcgWeeklySubcutaneous injection

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Consult prescriber before combining with any medicationCaution
BPC-157Compatible
NAD+Compatible
Vitamin DCompatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove VIP vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial effects and adaptation period. Monitor for any adverse reactions.

Week 2–4

Primary effects begin to manifest. Adjust dosing as recommended by your provider.

Week 4–8

Main therapeutic effects should be established. Assess progress with your provider.

Week 8+

Evaluate results and determine continuation, cycling, or dose adjustments.

Side Effects & Safety

  • Injection site reactions (redness, bruising, mild pain)
  • Potential for allergic reaction — discontinue if rash or hives occur
  • Individual reactions vary — start at the lowest dose and monitor carefully
  • Consult your healthcare provider before use and report any unusual symptoms

FDA Status & Regulatory Info

Compoundable

Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide naturally expressed throughout the nervous system, gut, and immune tissues. It functions as a potent immunomodulator, bronchodilator, and vasodilator. Clinically researched for inflammatory bowel disease, pulmonary arterial hypertension, sarcoidosis, autoimmune conditions, and CIRS (Chronic Inflammatory Response Syndrome). Available through compounding pharmacies with a prescription.

Rx Required: Yes
503A Ban: No
Telehealth: Available
Full FDA Status Tracker

Frequently Asked Questions

Research References

External links for education only. We do not control third-party content.

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

Community Intelligence

What 25 users report

25 community reports

Positive 2% · Neutral 2% · Negative 96%

Most reported benefits

Recovery
163
Energy
6

Most reported side effects

Nausea
83
Headache
77

Dose distribution

Median: 50–100 mcg · Most common: 50–100 mcg

0–25
0
25–50
0
50–100
116
100–200
47
200–400
0
400–600
0
600–1000
0
1000–2000
0
2000+
0

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 13% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 152 days · Based on 24 repeat reporters

Share Your Experience

Rate VIP in the PeptIQ app and help the community make informed decisions.

Research purposes only

This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.